Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, 1300 York Avenue, Box 62, New York, NY 10065-4896, USA.
Cell Microbiol. 2012 Aug;14(8):1183-92. doi: 10.1111/j.1462-5822.2012.01812.x. Epub 2012 Jun 5.
Infection by HIV starts when the virus attaches to a susceptible cell. For viral replication to continue, the viral envelope must fuse with a cellular membrane, thereby delivering the viral core to the cytoplasm, where the RNA genome is reverse-transcribed. The key players in this entry by fusion are the envelope glycoprotein, on the viral side, and CD4 and a co-receptor, CCR5 or CXCR4, on the cellular side. Here, the interplay of these molecules is reviewed from cell-biological, structural, mechanistic, and modelling-based perspectives. Hypotheses are evaluated regarding the cellular compartment for entry, the transfer of virus through direct cell-to-cell contact, the sequence of molecular events, and the number of molecules involved on each side of the virus-cell divide. An emerging theme is the heterogeneity among the entry mediators on both sides, a diversity that affects the efficacy of entry inhibitors, be they small-molecule ligands, peptides or neutralizing antibodies. These insights inform rational strategies for therapy as well as vaccination.
HIV 感染始于病毒附着于易感细胞。为了继续进行病毒复制,病毒包膜必须与细胞膜融合,从而将病毒核心递送至细胞质,在细胞质中,RNA 基因组被逆转录。在融合进入过程中,关键的参与者是病毒侧的包膜糖蛋白和细胞侧的 CD4 和共受体 CCR5 或 CXCR4。本文从细胞生物学、结构、机制和基于模型的角度综述了这些分子的相互作用。评估了关于进入的细胞区室、通过直接细胞间接触转移病毒、分子事件的顺序以及病毒-细胞分裂两侧涉及的分子数量的假说。一个新出现的主题是双方进入介质的异质性,这种多样性会影响进入抑制剂的效果,无论这些抑制剂是小分子配体、肽还是中和抗体。这些见解为治疗和疫苗接种提供了合理的策略。